WTA now requires one-time genetic sex testing — here’s what that actually means

Big, blunt headline: the WTA has introduced mandatory genetic sex testing for everyone on the women’s tour, using the presence of the SRY gene as the marker. It’s immediate, one-off, and intended by the tour to be about keeping things “fair” in women’s tennis — but it opens a lot of practical, legal and ethical questions that fans and players will want answers to.

What the policy actually says

Start with the mechanics. The WTA is asking every player to provide a sample — a cheek swab, blood, or saliva sample — so labs can check for the SRY gene. That test is described as a one-off, lifetime screen: once you’re cleared or further assessed, you shouldn’t have to repeat it. (That detail comes from the same reporting.)

How results are handled

If the SRY gene is not detected, the player can compete on the WTA Tour without further action. If the gene is detected, the policy says there will be additional medical assessment before a final decision on eligibility is reached.

The WTA frames the rule as distinguishing biological sex from gender identity and has explicitly said there is “no intent to disrespect or question the gender identity or the dignity of any person.” That phrasing — and the overall description of the policy — was outlined in reporting by ESPN.

Who this applies to

The notable twist here is scope: the requirement is for all players on the tour, not only athletes who self-identify as transgender or who were previously subject to separate screening. That makes it broader than past approaches which focused on specific groups.

How this compares to the previous rules

Three years ago the tour’s framework was different.

Under the WTA’s 2024 approach, transgender women could compete if they maintained testosterone levels below 2.5 nmol/L for two continuous years. That was an approach centered on hormone thresholds rather than chromosomal or genetic markers — a system many sports used because it focused on a measurable, current physiological condition rather than immutable genetics. The BBC reported this previous threshold and policy change in 2024.

Now the WTA has moved to a biological-sex based screening using the SRY gene. ESPN’s reporting also noted the Tour aligned its move with the International Olympic Committee’s March eligibility policy and framed it as part of a broader shift in women’s sport governance heading toward the 2028 Los Angeles Olympics.

Why the WTA says they’re doing this

The WTA is positioning the change as a fairness measure. In public language reported by ESPN, the tour says the test preserves competitive integrity for the women’s game.

That’s not a controversial-sounding goal at face value — every sports body talks about fairness — but choosing a genetic test as the mechanism is a pretty decisive move in how fairness is defined and enforced.

Practical, legal and privacy implications

This is where things get messy in real life.

• Testing and privacy. Asking every player for genetic material raises obvious medical-privacy questions. Who stores the samples? How long are records kept? Who can see the results? Media reporting doesn’t lay out protocol details — the headlines say the test is required and one-off, but finer points about data handling aren’t in the coverage I have.
• Governance and legal exposure. One outlet reported the policy is now governed under Florida law. That’s notable because legal frameworks differ around the world and could affect challenges to the rule if they arise.
• Enforcement and penalties. Reporting by commentator Ben Rothenberg includes a detail about a new acknowledgment form: refusal to test or competing while ineligible could lead to disciplinary action and, potentially, public disclosure of ineligibility. That’s Rothenberg’s reporting and assessment rather than a WTA press release, but it’s a serious procedural point to flag.

Who this affects — and who it doesn’t (for now)

One important empirical detail: the BBC reports there are no known transgender women currently playing on the WTA Tour. So whatever immediate competitive disruption people imagine — star players forced out, rankings upended overnight — there’s no reporting evidence that’s about to happen in practice.

That said, the policy affects every player administratively because everyone has to be screened. That breadth makes the rule operate differently than previous targeted checks.

How other commentators and outlets are reacting

There are a few distinct takes building in the coverage:

• Some see this as part of a broader movement in women’s sport toward biological-sex-based eligibility rules rather than testosterone-centered systems. ESPN’s story frames it in that context.
• Ben Rothenberg, writing in detail, called it likely the first independent professional women’s sports league or tour to require genetic sex screening for all athletes. That’s his reporting and assessment rather than an official WTA claim, but it’s worth noting as context.
• Other newsletters and specialist sites have dug into governance nuances, warning that placement under Florida law could matter if the policy is litigated or politically challenged.

What this doesn’t cover — and what the reporting leaves unclear

There are some gaps in the public reporting so far.

• Operational detail: there isn’t clear public information in the cited reports about sample storage, lab accreditation, data privacy safeguards, or appeal procedures after a positive test.
• Scientific nuance: the SRY gene is one marker among many that relate to sex determination. The news coverage reports the WTA chose SRY as the eligibility marker; the reporting doesn’t detail why SRY was selected over any other criteria or how edge cases will be managed medically.
• Actual impact: with no known transgender women currently on tour, the immediate competitive impact is unknown. The policy could be preventive, legal-protective, symbolic, or some mix of those things — the coverage doesn’t resolve that for us.

FAQ — the questions you’re probably asking

1. Is testing immediate and mandatory for all players?

Yes. The WTA’s updated policy requires all players to provide a sample for SRY testing, and reports say it’s effective immediately.

2. What sample do they collect?

The reporting says players will provide a cheek swab, blood, or saliva sample for the test.

3. Is the test a one-time thing?

Yes. Both BBC and other coverage describe the test as a one-off or lifetime test — once you’re screened, you won’t need routine retesting under this policy.

4. What happens if the test finds the SRY gene?

A positive SRY result triggers further medical assessment before a final eligibility decision is made, according to the reporting.

5. Are there already trans women on tour who’ll be affected?

News outlets report there are no known transgender women currently playing on the WTA Tour, so there’s no identified group of players immediately named in the coverage as affected.

6. Can a player refuse to be tested?

One report by Ben Rothenberg said a new acknowledgment form warns that refusing to test or competing while ineligible could lead to disciplinary action and possible public disclosure. That’s his reporting on the matter; the WTA’s formal process and any appeal mechanics weren’t fully detailed in the mainstream pieces.

What to watch next

There are a few things I’d be looking for in the coming weeks:

• Official WTA paperwork and privacy policies detailing sample handling and data protections.
• Any statements from players, players’ associations, or medical bodies responding to the test choice and how it will be implemented.
• Legal filings or challenges, especially since one report flagged governance under Florida law, which could shape jurisdictional fights.
• Further commentary or clarifications from the WTA about edge cases and the medical-assessment process for positive results.

Bottom line — the one thing to remember

The WTA has shifted from a hormone-based framework to a one-time genetic test for all players, using the SRY gene as the eligibility marker. The tour says it’s about fairness and aligns with wider sporting policy shifts, but the move raises substantial questions about privacy, medical nuance and legal exposure — and, importantly, the immediate competitive impact appears limited because reports say there are currently no known transgender women on tour.

This is a policy that will live in paperwork, courts, doctor’s offices and locker rooms — and the details matter. Keep an eye out for the WTA’s operational guidance and any player responses; that’s where we’ll see how this works in practice, not just on paper.